135 related articles for article (PubMed ID: 37150261)
1. Efficacy and Safety of Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer (MITO-RT2/RAD): A Large, Real-World Study in Collaboration With Italian Association of Radiation Oncology, Multicenter Italian Trials in Ovarian Cancer, and Mario Negri Gynecologic Oncology Group Groups.
Macchia G; Pezzulla D; Campitelli M; Laliscia C; Fodor A; Bonome P; Draghini L; Ippolito E; De Sanctis V; Ferioli M; Titone F; Balcet V; Di Cataldo V; Russo D; Vicenzi L; Cossa S; Lucci S; Cilla S; Deodato F; Gambacorta MA; Scambia G; Morganti AG; Ferrandina G
Int J Radiat Oncol Biol Phys; 2023 Oct; 117(2):321-332. PubMed ID: 37150261
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups.
Macchia G; Nardangeli A; Laliscia C; Fodor A; Draghini L; Gentile PC; D'Agostino GR; Balcet V; Bonome P; Ferioli M; Autorino R; Vicenzi L; Raguso A; Borghesi S; Ippolito E; Di Cataldo V; Cilla S; Perrucci E; Campitelli M; Gambacorta MA; Deodato F; Scambia G; Ferrandina G
Int J Gynecol Cancer; 2022 Jun; 32(6):732-739. PubMed ID: 35193941
[TBL] [Abstract][Full Text] [Related]
3. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
Macchia G; Lazzari R; Colombo N; Laliscia C; Capelli G; D'Agostino GR; Deodato F; Maranzano E; Ippolito E; Ronchi S; Paiar F; Scorsetti M; Cilla S; Ingargiola R; Huscher A; Cerrotta AM; Fodor A; Vicenzi L; Russo D; Borghesi S; Perrucci E; Pignata S; Aristei C; Morganti AG; Scambia G; Valentini V; Jereczek-Fossa BA; Ferrandina G
Oncologist; 2020 Feb; 25(2):e311-e320. PubMed ID: 32043791
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD).
Macchia G; Jereczek-Fossa BA; Lazzari R; Cerrotta A; Deodato F; Ippolito E; Aristei C; Gambacorta MA; Scambia G; Valentini V; Ferrandina G
Int J Gynecol Cancer; 2022 Jul; 32(7):939-943. PubMed ID: 34155084
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday.
Lazzari R; Ronchi S; Gandini S; Surgo A; Volpe S; Piperno G; Comi S; Pansini F; Fodor C; Orecchia R; Tomao F; Parma G; Colombo N; Jereczek-Fossa BA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):650-660. PubMed ID: 29893277
[TBL] [Abstract][Full Text] [Related]
6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis.
Onal C; Gultekin M; Oymak E; Guler OC; Yilmaz MT; Yuce Sari S; Akkus Yildirim B; Yildiz F
Int J Gynecol Cancer; 2020 Jun; 30(6):865-872. PubMed ID: 32273293
[TBL] [Abstract][Full Text] [Related]
8. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer.
Jereczek-Fossa BA; Piperno G; Ronchi S; Catalano G; Fodor C; Cambria R; Fossati Ing P; Gherardi F; Alterio D; Zerini D; Garibaldi C; Baroni G; De Cobelli O; Orecchia R
Am J Clin Oncol; 2014 Jun; 37(3):227-33. PubMed ID: 22992626
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers.
Reshko LB; Baliga S; Crandley EF; Harry Lomas IV; Richardson MK; Spencer K; Bennion N; Mikdachi HE; Irvin W; Kersh CR
Gynecol Oncol; 2020 Dec; 159(3):611-617. PubMed ID: 33059914
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer.
Macchia G; Cilla S; Pezzulla D; Campitelli M; Laliscia C; Lazzari R; Draghini L; Fodor A; D'Agostino GR; Russo D; Balcet V; Ferioli M; Vicenzi L; Raguso A; Di Cataldo V; Perrucci E; Borghesi S; Ippolito E; Gentile P; De Sanctis V; Titone F; Delle Curti CT; Huscher A; Gambacorta MA; Ferrandina G; Morganti AG; Deodato F
Gynecol Oncol; 2024 Jan; 184():16-23. PubMed ID: 38271773
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Body Radiation Therapy: A Versatile, Well-Tolerated, and Effective Treatment Option for Extracranial Metastases From Primary Ovarian and Uterine Cancer.
Aghdam N; Repka MC; McGunigal M; Pepin A; Paydar I; Rudra S; Paudel N; Pernia Marin M; Suy S; Collins SP; Barnes W; Collins BT
Front Oncol; 2020; 10():572564. PubMed ID: 33425723
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy in the treatment of ovarian cancer.
Kowalchuk RO; Waters MR; Richardson KM; Spencer K; Larner JM; Irvin WP; Kersh CR
Radiat Oncol; 2020 May; 15(1):108. PubMed ID: 32404167
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11).
Park HJ; Chang AR; Seo Y; Cho CK; Jang WI; Kim MS; Choi C
Anticancer Res; 2015 Sep; 35(9):5103-10. PubMed ID: 26254414
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic radiosurgery for intracranial hemangiopericytomas: a multicenter study.
Cohen-Inbar O; Lee CC; Mousavi SH; Kano H; Mathieu D; Meola A; Nakaji P; Honea N; Johnson M; Abbassy M; Mohammadi AM; Silva D; Yang HC; Grills I; Kondziolka D; Barnett GH; Lunsford LD; Sheehan J
J Neurosurg; 2017 Mar; 126(3):744-754. PubMed ID: 27104850
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review.
Yegya-Raman N; Cao CD; Hathout L; Girda E; Richard SD; Rosenblum NG; Taunk NK; Jabbour SK
Gynecol Oncol; 2020 Nov; 159(2):573-580. PubMed ID: 32917412
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers.
Lai TS; Francoeur A; Manrriquez E; Venkat P; Chang A; Douek M; Bahrami S; Raman SS; Memarzadeh S
Brachytherapy; 2024; 23(3):266-273. PubMed ID: 38453533
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer: Clinical Outcomes and Toxicity.
Reddy AV; Mills MN; Reshko LB; Martin Richardson K; Kersh CR
Cancer Invest; 2020 Sep; 38(8-9):522-530. PubMed ID: 32870714
[TBL] [Abstract][Full Text] [Related]
19. Volumetric intensity modulated arc therapy for stereotactic body radiosurgery in oligometastatic breast and gynecological cancers: feasibility and clinical results.
Macchia G; Deodato F; Cilla S; Torre G; Corrado G; Legge F; Gambacorta MA; Tagliaferri L; Mignogna S; Scambia G; Valentini V; Morganti AG; Ferrandina G
Oncol Rep; 2014 Nov; 32(5):2237-43. PubMed ID: 25175950
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of Stereotactic Body Radiation Therapy for Treatment of Adrenal Gland Metastases.
Scouarnec C; Pasquier D; Luu J; le Tinier F; Lebellec L; Rault E; Lartigau E; Mirabel X
Front Oncol; 2019; 9():732. PubMed ID: 31448234
[No Abstract] [Full Text] [Related]
[Next] [New Search]
